Therapeutic Outcome in Invasive Aspergillosis
نویسندگان
چکیده
منابع مشابه
Invasive Aspergillosis in Pediatric Hematology Oncology Ward
Background: Patients with prolonged neutropenia and/or severe underlying immunosuppression are at thegreatest risk for disseminated aspergillosis. This study was undertaken to determine the incidence of invasiveaspergillosis by Platelia Aspergillus enzyme-linked immunosorbent assay ELISA kit in high risk children admitted tothe hematology ward of Dr. Faghihi hospital, Shiraz University of Medic...
متن کاملEnhancing angiogenesis in invasive aspergillosis: a novel therapeutic approach.
Invasive aspergillosis is one of the most devastating opportunistic infections in immunocompromised hosts, such as those with hematologic malignancies and those undergoing hematologic cell transplantation (HCT). Despite the recent availability of potent antifungal agents, mortality rates remain unacceptably high for invasive aspergillosis in these 2 patient groups, at 42% and 58%–72%, respectiv...
متن کاملHost biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.
Invasive pulmonary aspergillosis (IPA) is a life-threatening disease of immunocompromised patients that requires aggressive therapy. Detection of the disease and monitoring of the therapeutic response during IPA are complex, and current molecular diagnostics are not suitably robust. Here, we explored proteomic profiles of bronchoalveolar lavage fluid (BALF) specimens from a persistently neutrop...
متن کاملTwo Cases of Invasive Pulmonary Aspergillosis in an Iranian Family
SUMMARY Aspergillosis is an infectious disease caused by genus aspergillos species. Aspergilli are ab undant in the environment, they Jive in soil as saprophyte deriving nutrient, from dead plants and animal matters. The genus aspergillos in characterized by the formation of distinctive conidiophores giving rise to conidias which can spread by air and are able to reside on the body surface spe...
متن کاملResponse assessment in invasive aspergillosis.
TO THE EDITOR—In a recent article published in Clinical Infectious Diseases, Nouér and colleagues recommend that the Aspergillus galactomannan index (GMI)–based response criteria be used as a primary endpoint in clinical trials of invasive aspergillosis (IA) rather than the European Organisation for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) outcome definitions [1] based o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 1996
ISSN: 1058-4838,1537-6591
DOI: 10.1093/clinids/23.3.608